3 June 2024 in Digital Discovery
Designing nanoparticles with desired properties is challenging due to the large combinatorial space and complex structure–function relationships. This process can be accelerated by combining microfluidics, high content imaging and active learning.
13 February 2024 in Small Methods
The performance of single‐chain polymeric nanoparticles (SCPNs) in biomedical applications highly depends on their conformational stability in cellular environments. Until now, such stability studies are limited to 2D cell culture models, which do not recapitulate the 3D tumor microenvironment well. Here, a microfluidic tumor‐on‐a‐chip model is introduced that recreates the tumor milieu and allows in‐depth insights into the diffusion, cellular uptake, and stability of SCPNs. The chip contains Matrigel/collagen‐hyaluronic acid as extracellular matrix (ECM) models and is seeded with cancer cell MCF7 spheroids. With this 3D platform, it is assessed how the polymer's microstructure affects the SCPN's behavior when crossing the ECM, and evaluates SCPN internalization in 3D cancer cells. A library of SCPNs varying in microstructure is prepared. All SCPNs show efficient ECM penetration but their cellular uptake/stability behavior depends on the microstructure. Glucose‐based nanoparticles display the highest spheroid uptake, followed by charged nanoparticles. Charged nanoparticles possess an open conformation while nanoparticles stabilized by internal hydrogen bonding retain a folded structure inside the tumor spheroids. The 3D microfluidic tumor‐on‐a‐chip platform is an efficient tool to elucidate the interplay between polymer microstructure and SCPN's stability, a key factor for the rational design of nanoparticles for targeted biological applications.
23 March 2023 in Nanoscale Advances
We introduce a machine-learning-assisted workflow to write, read, and classify dye-loaded PLGA–PEG nanoparticles at a single-particle level.
29 August 2023 in ChemRxiv
Designing nanoparticles with desired properties is a challenging endeavor, due to the large combinatorial space and complex structure-function relationships. High throughput methodologies and machine learning approaches are attractive and emergent strategies to accelerate nanoparticle composition design. To date, how to combine nanoparticle formulation, screening, and computational decision-making into a single effective workflow is underexplored. In this study, we showcase the integration of three key technologies, namely microfluidic-based formulation, high content imaging, and active machine learning. As a case study, we apply our approach for designing PLGA-PEG nanoparticles with high uptake in human breast cancer cells. Starting from a small set of nanoparticles for model training, our approach led to an increase in uptake from ~5-fold to ~15-fold in only two machine learning guided iterations, taking one week each. To the best of our knowledge, this is the first time that these three technologies have been successfully integrated to optimize a biological response through nanoparticle composition. Our results underscore the potential of the proposed platform for rapid and unbiased nanoparticle optimization.
21 October 2026 in Biomedicine & Pharmacotherapy
Hepatocellular carcinoma (HCC), or primary liver cancer, is one of the leading causes of mortality worldwide. Liver cirrhosis, characterized by deposition of excessive extracellular matrix (ECM) secreted by hepatic stellate cells (HSCs), is the major risk factor of HCC development. Although anti-fibrotic therapies hold great promise in the treatment of HCC, conventional non-animal models lack the complexity of the tumor microenvironment, especially its ECM component, driving efforts to develop more representative platforms. In this context, we bioengineered HCC spheroids by co-culturing human HCC cells (HepG2) with human HSCs (LX-2) in different ratios using a soft-embossed microwell array platform. HCC spheroids, depending on their exact composition, displayed typical HCC features, such as the presence of an ECM-rich capsule, as revealed by immunostaining of collagen type I on intact spheroids after tissue clearing. We hypothesized that the presence of this capsule, which is involved in several stages of tumor progression, could act as a 'protective barrier' that regulates the penetration and delivery of therapeutic agents. This hypothesis was confirmed using our bioengineered HCC spheroids, in which the combined presence of HSCs and ECM hinders the penetration and therapeutic efficacy of a model chemotherapeutics (doxorubicin). This could be improved by concomitant enzymatic degradation of the ECM-rich capsule. Altogether, we propose our HCC model as a relevant platform to study tumor-tumor microenvironment interactions, gain mechanistic insights into HCC, identify novel therapeutic targets and evaluate (combination) therapies targeting tumor-tumor microenvironment while integrating ECM degradation with the (targeted) delivery of therapeutic agents.